Key Takeaways
What Is Depression Screening?
Depression screening is a standard set of questions that helps a clinician find out whether a person has symptoms of, or is at risk of, depression[3]. The U.S. Preventive Services Task Force (USPSTF) recommends depression screening for the whole adult population, including pregnant and postpartum people and older adults, in its 2023 statement[1].
A screen is not a diagnosis. MedlinePlus notes that a provider needs further evaluation, and possibly a referral to a mental health provider, to tell whether someone actually has depression[3]. The diagnostic rules clinicians apply are covered in DSM-5 depression criteria.
Named screening tools include the Patient Health Questionnaire-9 (PHQ-9), Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAM-D), Zung Self-Rating Depression Scale and the Geriatric Depression Scale (GDS and its short form)[3]. No special preparation is needed[3].
This article covers how screening is recommended, done and paid for. Figures on how many Americans have major depressive disorder are kept on the condition pages.
Who Should Get Depression Screening?
The USPSTF recommends screening for depression in adults with a grade B, and the recommendation names pregnant and postpartum people and adults 65 or older[1]. A separate 2022 USPSTF statement gives a grade B to screening for major depressive disorder in adolescents aged 12 to 18[2].
For children 11 or younger, the task force found the evidence insufficient to weigh benefits against harms, an I statement rather than a recommendation against screening[2]. It reached the same I statement for screening for suicide risk, both in adults and in children and adolescents[1][2].
The American College of Obstetricians and Gynecologists (ACOG) goes further for pregnancy. Its 2023 guideline recommends screening everyone receiving well-woman, prepregnancy, prenatal and postpartum care for depression and anxiety, at the first prenatal visit, later in pregnancy and at postpartum visits[5]. Data on postpartum depression are tracked separately.
How often to screen is unsettled. The USPSTF found little evidence on timing and suggests screening adults who have not been screened before, then using clinical judgment about risk factors, other conditions and life events[1].
For teens, it found no evidence on the right interval and noted that repeat screening may be most productive in adolescents with risk factors[2]. Rates among teens are on the adolescent depression page.
Depression Screening Recommendations by Group
| Group | Recommendation | Source |
|---|---|---|
| Adults | Screen for depression (grade B) | USPSTF, 2023 |
| Pregnant and postpartum people | Screen (grade B); ACOG: first prenatal visit, later pregnancy, postpartum | USPSTF, 2023; ACOG, 2023 |
| Adults 65 and older | Screen for depression (grade B) | USPSTF, 2023 |
| Adolescents 12 to 18 | Screen for major depressive disorder (grade B) | USPSTF, 2022 |
| Children 11 and younger | Insufficient evidence (I statement) | USPSTF, 2022 |
| Suicide risk, all ages | Insufficient evidence (I statement) | USPSTF, 2022 and 2023 |
Current U.S. depression screening recommendations for people without a diagnosed condition or recognized symptoms, by group[1][2][5].
1An I statement means the evidence is insufficient to assess the balance of benefits and harms; it is not a recommendation against screening[2].
2ACOG also advises screening for bipolar disorder before starting medication for depression or anxiety, if not previously done[5].
Sources
- •USPSTF, 2023
- •USPSTF, 2022
- •ACOG, 2023
How Depression Screening Works: PHQ-2, PHQ-9 and Other Tools
The PHQ-2 is the first 2 items of the PHQ-9, which ask how often a person has had depressed mood and loss of interest (anhedonia), and it can serve as a first step before the full form[4].
PHQ-2 scores run from 0 to 6 and PHQ-9 scores from 0 to 27[4]. In the common two-step approach, a PHQ-2 score of 2 or more prompts the full PHQ-9, and a PHQ-9 score of 10 or more counts as a positive screen[4].
Item-by-item scoring and severity bands are covered in the PHQ-9 depression test guide. Self-administered online screeners exist as well; the Mental Health America depression test article explains how one is scored.
For adolescents, the PHQ-9 is the most commonly used instrument in practice, and the PHQ-A (a version modified for adolescents) and the Center for Epidemiologic Studies Depression Scale (CES-D) have also been studied[2].
In pregnancy and after birth, ACOG's toolkit offers screeners built on either the Edinburgh Postnatal Depression Scale (EPDS) or the PHQ-9, each combined with the Mood Disorder Questionnaire (MDQ), the GAD-7 anxiety scale and a PTSD screen[5]. ACOG also advises a bipolar disorder screen before starting antidepressants, noting that 1 in 5 women who screen positive for depression may have bipolar disorder[5].
How Accurate Is Depression Screening?
In the evidence reviewed for the 2023 USPSTF statement, the PHQ-9 at the standard cutoff of 10 identified 85% of people with major depression and 85% of those without it, compared with a semistructured diagnostic interview (47 studies, 11,234 participants)[1].
The PHQ-2 at a cutoff of 2 or more is more sensitive, catching 91% of cases, but correctly clears only 67% of people without depression[4]. Raising the PHQ-2 cutoff to 3 reverses the tradeoff: sensitivity falls to 72% and specificity rises to 85%[4].
Running the PHQ-2 (2 or more) and then the PHQ-9 (10 or more) gave 82% sensitivity and 87% specificity, statistically similar sensitivity to the PHQ-9 alone, while cutting the number of people who had to complete the full PHQ-9 by 57%[4]. That 2020 meta-analysis pooled individual data from 100 studies and 44,318 participants[4].
For adolescents, one study of the PHQ-A found 73% sensitivity and 94% specificity[2]. Two studies of the CES-D in teens reported sensitivity from 59% to 85% and specificity from 38% to 83%, depending on the threshold[2].
Accuracy of Common Depression Screening Tools
| Tool | Positive if | Sensitivity | Specificity |
|---|---|---|---|
| PHQ-2 | Score of 2 or more | 91% | 67% |
| PHQ-2 | Score of 3 or more | 72% | 85% |
| PHQ-9 | Score of 10 or more | 86% | 85% |
| PHQ-2, then PHQ-9 | 2 or more, then 10 or more | 82% | 87% |
| PHQ-A (adolescents) | Single study | 73% | 94% |
Sensitivity and specificity for detecting major depression compared with semistructured diagnostic interviews; adult figures from a 2020 individual participant data meta-analysis[4], adolescent figure from the 2022 USPSTF review[2].
1The USPSTF's 2023 estimate for the PHQ-9 alone at a cutoff of 10 is 85% sensitivity and 85% specificity (47 studies)[1].
Sources
- •Levis et al., JAMA, 2020
- •USPSTF, 2022
- •USPSTF, 2023
Sensitivity and specificity
Sensitivity is the share of people who have a condition that a screening test flags as positive. Specificity is the share of people without the condition that the test correctly clears. A PHQ-2 cutoff of 2 has high sensitivity (91%) but lower specificity (67%), so it misses few cases but flags many people who do not have major depression[4].
Related Terms
Source: Levis et al., JAMA, 2020
U.S. primary care encounters that included a depression screen, 2010 to 2018
Drawn from the National Ambulatory Medical Care Survey. Screening rose over the period but stayed infrequent, even though depression was far more likely to be diagnosed when a screen took place.
"Patients were screened for depression 4.1% of the time"
How Often Does Depression Screening Happen in Practice?
National survey data show a wide gap between the recommendation and routine care. In the 2010 to 2018 National Ambulatory Medical Care Survey, patients were screened for depression in 4.1% of primary care encounters, with screening increasing over time[7].
When screening did happen, depression was much more likely to be diagnosed (odds ratio 9.9)[7]. An earlier analysis of 2012 and 2013 data, covering 33,653 visits by adults without existing depression, found a 4.2% screening rate, and 47% of screened visits resulted in a new depression diagnosis[6].
Screening was uneven. African American patients were half as likely as white patients to be screened, patients 65 or older were less likely to be screened than middle-aged patients (adjusted odds ratio 0.48), and practices with full electronic health records screened more than those using paper charts[6].
Systematic programs change the picture. After one large integrated health system began routine PHQ screening in mid-2016, 59% of 259,411 patients were screened, 3% scored in the moderate-to-severe range, and the depression diagnosis rate rose from 1.7% to 2.9%[8].
In the same system, the share of patients diagnosed with depression who were treated within 90 days rose from 64% to 69%[8].
Does Depression Screening Improve Outcomes?
The USPSTF based its 2023 recommendation on 17 screening trials that showed higher rates of depression remission, or of scoring below a symptom threshold, after 6 to 12 months in general adult and perinatal populations[1].
Pooling 8 randomized trials with 10,244 participants, screening interventions were associated with lower odds of depression or clinically important symptoms at about 6 months (odds ratio 0.60)[1]. Among participants above a symptom threshold at the start, screening was associated with higher odds of remission (odds ratio 1.58; 8 trials, 2,302 participants)[1].
Most of those interventions also included care management, so the trials test screening plus follow-up rather than a questionnaire alone[1]. The evidence in older adults showed smaller effects[1].
The task force states that adequate systems and clinical staff are needed so that people who screen positive are diagnosed and treated or referred, and that inadequate support and follow-up may result in treatment failures or harm[1].
Evidence on suicide risk screening is thin. Only 1 short-term randomized trial (443 participants) examined it, and it found no significant difference in suicidal ideation at 2 weeks[1].
What Happens After a Positive Depression Screen?
A positive screen leads to further evaluation. MedlinePlus notes that the provider will need to do more assessment, and possibly refer the person to a mental health provider, to determine whether depression is present[3].
The USPSTF lists the follow-up functions screening depends on: accurate diagnosis, evidence-based treatment or referral, and support such as collaborative care, a model in which care managers link primary care clinicians, patients and mental health specialists[1].
In perinatal care, ACOG advises that screens be scored before the patient leaves the appointment so a positive result can be addressed promptly[5]. An affirmative answer to a self-harm or suicide question should prompt an immediate assessment of risk[5].
On treatment, the USPSTF review found a moderate to large effect of psychotherapy across 385 studies (standardized mean difference -0.72), smaller in primary care patients (-0.42; 59 studies)[1]. Pooled antidepressant trials showed higher remission and response rates and small short-term reductions in symptom severity[1].
The trial evidence for each option is covered in cognitive behavioral therapy for depression and antidepressant medications.
Is Depression Screening Covered by Insurance?
Medicare Part B covers 1 depression screening a year, and the beneficiary pays nothing if the provider accepts assignment[10]. The screening must take place in a primary care setting that can provide follow-up treatment or referrals to a mental health provider[10].
CMS added the benefit in a decision memo dated October 14, 2011[9]. It requires staff-assisted depression care supports: at a minimum, clinical staff who can advise the physician of screening results and coordinate referrals to mental health treatment[9].
HealthCare.gov lists depression screening among the adult preventive services that all Marketplace plans and many other plans must cover without a copayment or coinsurance, even before the deductible is met[11]. It adds that $0 cost is generally tied to in-network providers and is not guaranteed in every case[11].
Follow-up care is billed separately. Medicare notes that later treatment or visits to a mental health provider may carry a copayment or coinsurance[10].
Frequently Asked Questions
Sources & References
- US Preventive Services Task Force. Depression and Suicide Risk in Adults: Screening. US Preventive Services Task Force. Published 2023. Accessed October 2026. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults [Link]
- US Preventive Services Task Force. Depression and Suicide Risk in Children and Adolescents: Screening. US Preventive Services Task Force. Published 2022. Accessed October 2026. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-children-adolescents [Link]
- Depression Screening. MedlinePlus, National Library of Medicine. Accessed October 2026. https://medlineplus.gov/lab-tests/depression-screening/ [Link]
- Levis B, Sun Y, He C, et al. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. JAMA. Published 2020. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/32515813/ [Link]
- American College of Obstetricians and Gynecologists. Patient Screening: Perinatal Mental Health Toolkit. American College of Obstetricians and Gynecologists. Published 2023. Accessed October 2026. https://www.acog.org/programs/perinatal-mental-health/patient-screening [Link]
- Akincigil A, Matthews EB. National Rates and Patterns of Depression Screening in Primary Care: Results From 2012 and 2013. Psychiatric Services. Published 2017. Accessed October 2026. https://www.psychiatryonline.org/doi/full/10.1176/appi.ps.201600096 [Link]
- Jackson JL, Kuriyama A, Bernstein J, Demchuk C. Depression in Primary Care, 2010-2018. The American Journal of Medicine. Published 2022. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/35878693/ [Link]
- Pfoh ER, Janmey I, Anand A, Martinez KA, Katzan I, Rothberg MB. The Impact of Systematic Depression Screening in Primary Care on Depression Identification and Treatment in a Large Health Care System: A Cohort Study. Journal of General Internal Medicine. Published 2020. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/32495093/ [Link]
- Centers for Medicare & Medicaid Services. Screening for Depression in Adults (CAG-00425N): Decision Memo. Centers for Medicare & Medicaid Services. Published 2011. Accessed October 2026. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=251 [Link]
- Depression Screening Coverage. Medicare.gov, Centers for Medicare & Medicaid Services. Accessed October 2026. https://www.medicare.gov/coverage/depression-screening [Link]
- Preventive Care Benefits for Adults. HealthCare.gov, Centers for Medicare & Medicaid Services. Accessed October 2026. https://www.healthcare.gov/preventive-care-adults/ [Link]